Cellestial Health raises pre-seed funding led by Zinc VC to advance its astrocyte-targeted drug development for brain disorders.
Cellestial Health raises pre-seed funding led by Zinc VC to advance its astrocyte-targeted drug development for brain disorders.
05/09/25, 7:59 AM
Location
cambridgeIndustry
therapeutics
biotechnology
health care
Round Type
pre-seed
Investors
Alma Angels, Sfc Capital, Zinc Vc
Cellestial Health has successfully raised pre-seed funding, led by Zinc VC and supported by SFC Capital and Angel investors. The funding will help develop innovative treatments targeting astrocytes for neurodegenerative diseases. Additionally, the company received £340k in grant funding from Parkinson’s UK and Cambridge Enterprise. Their approach seeks to revolutionize brain disorder treatments by restoring normal astrocytic functions.
Company Info
Location
cambridge, england, united kingdom
Additional Info
Cellestial Health is focused on revolutionizing the treatment of brain disorders by incorporating astrocytes into drug development. The company aims to develop brain-permeable small molecule drugs that restore normal astrocytic network function, offering a new pathway for neurodegenerative conditions like Parkinson's disease. Built on years of academic research, Cellestial validates its drug targets and collaborates with leading drug discovery experts to advance its innovative therapeutics. Their mission addresses the urgent need for treatments that go beyond symptom management in neurodegenerative diseases.